RC118
Phase 2Small molecule
RC118 is one of 6 small molecule programs targeting Locally Advanced Unresectable or Metastatic Solid Tumors. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Locally Advanced Unresectable or Metastatic Solid Tumors
#DrugCompanyPhaseTrials
1Tuoyi
CCoherus Oncology, Inc.
Phase 2
RC148
RRemeGen Co., Ltd.
Phase 2
IBI343
Innovent Biologics (Suzhou) Co. Ltd.Phase 1
IBI354
Innovent Biologics (Suzhou) Co. Ltd.Phase 2
RC118
RRemeGen Co., Ltd.
Phase 2
Mfolfox
Arcus BiosciencesPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RC118. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRemeGen Co., Ltd.